A new meta-analysis led by researchers in Japan investigates whether lithium (LIT) supplementation can slow cognitive decline in individuals with mild cognitive impairment (MCI) or Alzheimer’s disease (AD). Building on preclinical evidence of LIT’s neuroprotective effects, the study systematically evaluates data from six randomized controlled trials to clarify its clinical potential. The findings aim to shed light on whether LIT, long used in psychiatry, could play a future role in MCI or AD prevention or treatment.

“Drains” in the brain, responsible for clearing toxic waste in the organ, tend to get clogged up in people who show signs of developing Alzheimer’s disease, a study by researchers from Nanyang Technological University, Singapore (NTU Singapore) has discovered. This suggests that such clogged drains, a condition known as “enlarged perivascular spaces”, are a likely early-warning sign for Alzheimer’s, a common form of dementia.

A study unveils a novel strategy to combat Alzheimer’s disease (AD) by targeting muscle health. Researchers found that skeletal muscles, through the protein Cathepsin B (Ctsb) released during exercise, can protect cognitive function. In AD-model mice, boosting muscle Ctsb improved memory and motor skills, even without reducing classic brain plaques. The treatment promoted hippocampal cell growth and restored critical protein balance, revealing a powerful muscle-brain connection. This work suggests exercise, gene therapy or drugs that enhance muscle Ctsb could offer a promising new avenue against cognitive decline.